Disposal

Stem Cell Sciences plc 09 November 2007 Press Release SCS REGAINS ALL OUTSTANDING RIGHTS TO COMMERCIALISE ITS NS CELL TECHNOLOGY PLATFORM GLOBALLY ("Stem Cell Sciences", "SCS") 9th November 2007 Stem Cell Sciences plc (AIM: STEM, ASX: STC) today announces that the company has secured all outstanding rights to commercialise its neural stem (NS) cell technology for both research and stem-cell based therapies. The recovery of these rights from SCS KK (Japan) completes a series of transactions through which SCS plc and SCS KK have become fully independent companies. SCS plc has retained the right to use the Stem Cell Sciences company name in Japan and has fully divested its shareholding in SCS KK. With the conclusion of this transaction, Dr Peter Mountford, CEO of SCS plc, will leave the Board of SCS KK. At 30 September 2007, the carrying value of SCS Group investment in SCS KK was £25,000. Commenting on the agreement, Dr Mountford said: "These changes simplify our respective businesses, enabling both companies to focus now on their different areas of interest and to have unhindered access to worldwide markets. Regaining full global rights to our NS cell technology will enable us to accelerate development and licensing of these cells, which are already in successful use for drug discovery with a number of biotechnology and pharmaceutical companies. A key focus for SCS is to ensure that we fully develop the commercial potential of all our stem cell technologies in basic and applied research. This transaction will help to achieve that objective." - Ends - For further information, please contact: Stem Cell Sciences plc (United Kingdom) +44 131 662 9829 Peter Mountford, President and CEO Halsin Partners (Media & Investors - EU/US) +44 20 7084 5955 Mike Sinclair Stem Cell Sciences (Australia) pty ltd +61 3 9905 0600 David Newton, General Manager Talk Biotech (Media & Investors - Australia/Asia) +61 422 206036 Fay Weston Stem Cell Sciences llc (USA) +1 415 495 7340 George Murphy, Vice President Business Development Notes to Editors Stem Cell Sciences plc (SCS, AIM: STEM, ASX: STC) is a global biotechnology company providing the biological infrastructure of cells and cell culture media to the burgeoning stem cell research market. Stem Cell Sciences' core objective is to develop safe and effective cell-based therapies for currently incurable diseases. SCS retains all rights to its technology for therapeutic use and is targeting cell-based therapies for neurodegenerative disease and injury. Revenues from Stem Cell Sciences' research business are delivered via an integrated network of business teams and regional offices in Edinburgh and Cambridge (UK), Melbourne (Australia) and San Francisco (USA). This global reach provides the Company with the direct access to markets through experienced personnel and local business networks needed to drive SCS's business growth in each region. The key challenge for the successful application of stem cells in both research and clinical applications is the reproducible supply of pure, fully characterized stem cells and stem cell-derived specialised cells such as nerves and muscle. This represents a significant technological challenge that will require access to multiple technologies and a globally integrated stem cell initiative. To access cutting edge technologies on a rapid and on-going basis, Stem Cell Sciences has built an exceptional network of highly interactive collaborations with academic centres of excellence in the stem cell field. These collaborations have been the source of our founding technologies and continue to provide an expanding pipeline of products and intellectual property that are central to the Company's strategy and success. To facilitate research and technology transfer with its major collaborating academic institutions, Stem Cell Sciences' business and scientific teams are usually co-located on site or adjacent to the centre of excellence in independent company facilities. The Company's key collaborating institutes include the Wellcome Trust Centre for Stem Cell Research (University of Cambridge), the Institute of Stem Cell Research (University of Edinburgh), RIKEN Centre for Developmental Biology (Kobe) and the Australian Stem Cell Centre (Melbourne). Academic and commercial use of stem cells in basic research and drug discovery provides the Company with immediate and growing revenue streams and offsets the cost of technology development for full scale cell production of SCS cell-based therapeutics. For further information on the company please visit: www.stemcellsciences.com This information is provided by RNS The company news service from the London Stock Exchange

Companies

SThree (STEM)
UK 100

Latest directors dealings